DrugPatentWatch Database Preview
Abraxis Bioscience Company Profile
What is the competitive landscape for ABRAXIS BIOSCIENCE, and when can generic versions of ABRAXIS BIOSCIENCE drugs launch?
ABRAXIS BIOSCIENCE has one approved drug.
There are twelve US patents protecting ABRAXIS BIOSCIENCE drugs.
Summary for Abraxis Bioscience
| US Patents: | 12 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Abraxis Bioscience: | See patent lawsuits for Abraxis Bioscience |
Drugs and US Patents for Abraxis Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 8,853,260 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 8,138,229 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 7,758,891 | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 9,597,409 | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 9,393,318 | ➤ Sign Up | ➤ Sign Up | ||||
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RX | Yes | Yes | 8,268,348 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abraxis Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 5,439,686 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 6,537,579 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 6,506,405 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 6,096,331 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | RE41884 | ➤ Sign Up |
| Abraxis Bioscience | ABRAXANE | paclitaxel | FOR SUSPENSION;IV (INFUSION) | 021660-001 | Jan 7, 2005 | 5,498,421 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABRAXIS BIOSCIENCE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection Suspension | 100 mg/vial | ➤ Subscribe | 2015-12-11 |
Non-Orange Book US Patents for Abraxis Bioscience
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,537,579 | Compositions and methods for administration of pharmacologically active compounds | ➤ Sign Up |
| 5,916,596 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | ➤ Sign Up |
| 5,512,268 | Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof | ➤ Sign Up |
| 5,560,933 | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor | ➤ Sign Up |
| 6,749,868 | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof | ➤ Sign Up |
| 7,780,984 | Methods and compositions for treating proliferative diseases | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Abraxis Bioscience Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2509365 | ➤ Sign Up |
| Mexico | 2009004803 | ➤ Sign Up |
| Russian Federation | 2009110382 | ➤ Sign Up |
| Taiwan | 201136584 | ➤ Sign Up |
| South Africa | 200707491 | ➤ Sign Up |
| Germany | 122009000065 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Abraxis Bioscience Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0961612/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014 |
| 8 50005-2014 | Slovakia | ➤ Sign Up | PRODUCT NAME: PAKLITAXEL VO FORME NANOCASTIC VIAZANYCH NA ALBUMIN; REGISTRATION NO/DATE: EU/1/07/428/001 - EU/1/07/428/002 20131230 |
| 0673 | Netherlands | ➤ Sign Up | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| /2014 | Austria | ➤ Sign Up | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
| 613 | Luxembourg | ➤ Sign Up | 91613, EXPIRES: 20220924 |
| 41/2009 | Austria | ➤ Sign Up | PRODUCT NAME: PACLITAXEL ALBUMIN |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
